Wall Street Remains Bullish On Lantheus Holdings, Inc. (LNTH)

Core Viewpoint - Lantheus Holdings, Inc. (NASDAQ:LNTH) is considered a promising investment in the healthcare sector, with a significant portion of analysts recommending a 'Buy' rating and a median price target indicating potential upside [1][2]. Analyst Ratings - Approximately 80% of analysts covering Lantheus Holdings have assigned a 'Buy' or equivalent rating, with a median price target of $75, suggesting an upside potential of 18.48% from the current price [1]. - Jefferies analyst Matthew Taylor maintains a 'Buy' rating with a price target of $105, indicating a potential upside of 66% [2]. - Leerink Partners has reduced its price target from $97 to $90 while keeping an 'Overweight' rating, citing concerns over pricing pressures and competitive dynamics affecting the Pylarify franchise [3]. Financial Performance - In the third quarter results announced on November 6, Lantheus reported mixed financial outcomes, with revenue exceeding consensus estimates by approximately 5%, while diluted EPS fell 2% short of expectations [4]. - The decline in Pylarify revenues was attributed to "340B best price-driven price compression and competitive pressures from Ga-68 PSMA PET agents at large accounts" [4]. Company Overview - Lantheus Holdings, Inc. is a Massachusetts-based company that specializes in diagnostic and therapeutic products for various diseases, with a history dating back to 1956 [4].